Patents by Inventor Maribel Guerra Vallespi
Maribel Guerra Vallespi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140206621Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: November 8, 2013Publication date: July 24, 2014Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Patent number: 8729226Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: GrantFiled: May 31, 2011Date of Patent: May 20, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Patent number: 8673313Abstract: The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein Limulus antilipopolisacárido (LALF) and its analogous. This invention refers to compositions containing these peptides associated to biomolecules with therapeutics properties. This invention consist of compositions comprise the covalent fusion of biomolecules, between this human papillomavirus antigens (HPV) to these CPP for induce a potent immune cellular responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors. The referred compositions are applicable in the pharmaceutical industry as vaccine for therapeutic use in human.Type: GrantFiled: July 31, 2008Date of Patent: March 18, 2014Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Isis del Carmen Torrens Madrazo, Maribel Guerra Vallespi, Milaid Granadillo Rodriguez, Osvaldo Reyes Acosta, Boris Ernesto Acevedo Castro
-
Publication number: 20130224313Abstract: This invention describes a method for treating cancer by increasing the nuclear localization of the COMMD1 protein, which is associated with decreasing or blocking the proliferation of the cancer cell. The invention is also related to the use of agents that increase nuclear localization of the COMMD1 protein, in the manufacture of a medicament for cancer therapy. These agents can be peptides or proteins, among other compounds. The invention is also related to the optimization of a peptide, coming from the sequence HARIKPTFRRLKWKKYKGKFW, to increase the nuclear localization of the protein COMMD, and thus, to increase the antitumor effect of this peptide.Type: ApplicationFiled: May 31, 2011Publication date: August 29, 2013Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Maribel Guerra Vallespi, Julio Raúl Fernández Massó, Alexis Musacchio Lasa, Jeovanis Gil Valdés, Osvaldo Reyes Acosta, Brizaida Maylin Oliva Argüelles
-
Patent number: 8283324Abstract: The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKYKGKFW (SEQ ID NO.: 13), showing amino acid substitutions, these peptides unable to bind to the lipopolysaccharides and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.Type: GrantFiled: February 23, 2007Date of Patent: October 9, 2012Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Maribel Guerra Vallespi, Isis del Carmen Torréns Madrazo, Osvaldo Reyes Acosta, Hilda Elisa Garay Pérez, Gerardo Enrique Guillén Nieto, Boris Ernesto Acevedo Castro, Raimundo Ubieta Gómez
-
Publication number: 20120135021Abstract: The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein Limulus antilipopolisacárido (LALF) and its analogous. This invention refers to compositions containing these peptides associated to biomolecules with therapeutics properties. This invention consist of compositions comprise the covalent fusion of biomolecules, between this human papillomavirus antigens (HPV) to these CPP for induce a potent immune cellular responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors. The referred compositions are applicable in the pharmaceutical industry as vaccine for therapeutic use in human.Type: ApplicationFiled: July 31, 2008Publication date: May 31, 2012Inventors: Isis del Carmen Torens Madrazo, Maribel Guerra Vallespi, Milaid Granadillo Rodriguez, Osvaldo Reyes Acosta, Boris Ernesto Acevedo Castro
-
Publication number: 20090221508Abstract: The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKKYKGKFW, showing aminoacids substitutions, these peptides unable to bind to the lipopolysaccharide and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.Type: ApplicationFiled: February 23, 2007Publication date: September 3, 2009Inventors: Maribel Guerra Vallespi, Isis del Carmen Torrrens Madrazo, Osvaldo Reyes Acosta, Hilda Elisa Garay Perez, Gerardo Enrique Guillen Nieto, Boris Ernesto Acevedo Castro, Raimundo Ubieta Gomez
-
Patent number: 7012127Abstract: The present invention relates to analogues of peptides from lipopolysaccharide-binding protein (LBP) region whose primary sequence have been substituted at particular amino acid sites to obtain effective binding to, and neutralization of, lipopolysaccharide (LPS).Type: GrantFiled: June 6, 2000Date of Patent: March 14, 2006Assignee: Centro de Ingenicria Genetica y BiotecnologiaInventors: Manuel de Jesús Araña Rosainz, Glay Chinea Santiago, Maribel Guerra Vallespi, Osvaldo Reyes Acosta
-
Patent number: 6632793Abstract: The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) Induce an antiviral state in both the Hep-2 and MDBK cell lines, (2) Supernatant from human mononuclear cells stimulated with peptide Limulus anti-LPS factor (LALF) is able to induce antiviral effect on Hep-2 cell line by mean of IFN-&ggr; (3) LALF peptide is able to modulate the immune response in vitro and in vivo. The present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune responses, without stimulating the production of certain biochemical mediators (e.g., TNF-&agr;) that can cause detrimental effects, such as fever and inflammation.Type: GrantFiled: October 18, 2000Date of Patent: October 14, 2003Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Maribel Guerra Vallespi, Manuel de Jesus Arana Rosianz
-
Publication number: 20020107201Abstract: The present invention is for a pharmaceutical composition comprising an effective amount of an lipopolysaccharide (LPS) binding and -neutralizing peptide. The LPS binding and neutralizing peptides of the present invention are analogues of peptides from a lipopolysaccharide binding protein region whose primary sequence have been substituted at particular amino acid sites to obtain an effective binding to and neutralization of LPS.Type: ApplicationFiled: October 31, 2001Publication date: August 8, 2002Applicant: Centro de Ingenieria genetica y biotecnologiaInventors: Manuel de Jesus Arana Rosainz, Santiago Chinea Glay, Maribel Guerra Vallespi, Osvaldo Reyes Acosta
-
Patent number: 6191114Abstract: The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) induce an antiviral state in both the Hep-2 and MDBK cell lines, (2) Supernatant from human mononuclear cells stimulated with peptide Limulus anti-LPS factor (LALF) is able to induce antiviral effect on Hep-2 cell line by mean of IFN-&ggr; (3) LALF peptide is able to modulate the immune response in vitro and in vivo. The present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune responses, without stimulating the production of certain biochemical mediators (e.g., TNF-&agr;,) that can cause detrimental effects, such as fever and inflammation.Type: GrantFiled: September 25, 1998Date of Patent: February 20, 2001Assignee: Centro de Ingenieria Genetica Y BiotecnologiaInventors: Maribel Guerra Vallespi, Manuel de Jesus Arana Rosainz